Elevated Treasury yields near 5.3% and investor caution around AI spending have tempered the pace of larger offerings, yet multiple IPOs have priced in early October 2026, including biotech names like TRex Bio and Retension Pharmaceuticals, with Iambic Therapeutics and City Therapeutics slated for mid-month. Goldman Sachs forecasts record U.S. equity issuance through year-end, supported by a deep pipeline of AI infrastructure and consumer filings, while Anthropic targets a November debut that could unlock further activity ahead of midterms. OpenAI has shifted to 2027, illustrating how rate sensitivity and valuation gaps can delay marquee deals even as smaller transactions continue. Trader consensus on near-term IPO completions reflects this mix of resilient filing activity and execution risk tied to macroeconomic stability.